Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary Results
Open Access
- 1 October 2010
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 9 (5), 479-487
- https://doi.org/10.1177/153303461000900506
Abstract
Stereotactic radiotherapy (SRT) offers a treatment option for hepatocellular carcinoma (HCC) patients that are not eligible for surgery, embolization, chemotherapy, or radiofrequency ablation. We have evaluated the feasibility, tolerance and toxicity of SRT for 25 HCC patients who were not eligible for these other modalities. The patients (6 women and 19 men) were treated with CyberKnife stereotactic radiotherapy using respiratory motion tracking. All patients had liver cirrhosis with an Eastern Cooperative Oncology Group (ECOG) performance score of less than 2 and pre-treatment Child scores ranging from A5 to B9. A total dose of 45 Gy in three fractions of 15 Gy each was prescribed to the 80% isodose line (95% of the PTV received 45 Gy) and delivered to the target volume over 10 to 12 days. Overall the treatment was well tolerated with two Grade 3 acute toxicities and no acute Grade 4 toxicities. Late toxicity was minimal with all observed late toxicities occurring within the first six months of follow-up. Three hepatic recurrences at a distance from the target and one metastasis were observed. The actuarial 1- and 2-year local control rate was 95% (95% CI: 69–95%). At a median overall follow-up of 12,7 months (range, 1–24 months), six of the twenty-five (24%) patients have died. Overall actuarial survival at 1- and 2-years was 79% (95% CI: 52–92%) and 52% (95% CI: 19–78%), respectively. Our results suggest promising therapeutic efficacy and good clinical tolerance to CyberKnife SRT treatment for HCC patients not eligible for other treatment modalities.Keywords
This publication has 40 references indexed in Scilit:
- Image-Guided Interstitial High-Dose-Rate Brachytherapy in Hepatocellular CarcinomaDigestive Diseases, 2009
- Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysisBMC Cancer, 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008
- Detection of Circulating Endothelial Cells: CD146-Based Magnetic Separation Enrichment or Flow Cytometric Assay?Journal of Clinical Oncology, 2007
- Stereotactic radiotherapy of primary liver cancer and hepatic metastasesActa Oncologica, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeThe New England Journal of Medicine, 2005
- Treatment of hepatocellular carcinoma: is there an optimal strategy?Cancer Treatment Reviews, 2003
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000